Carlos von Bonhorst
Keine laufenden Positionen mehr
Profil
Carlos von Bonhorst worked as Director of Corporate Development at Helsinn Healthcare SA from 1985 to 1993.
He also worked as Director of Business Development at Biofarma Lda.
from 1975 to 1985.
He was an Independent Director at Recipharm AB.
Dr. von Bonhorst earned a doctorate degree from the University of Lisbon in 1981.
Ehemalige bekannte Positionen von Carlos von Bonhorst
| Unternehmen | Position | Ende |
|---|---|---|
Helsinn Healthcare SA
 Helsinn Healthcare SA Pharmaceuticals: MajorHealth Technology Helsinn Healthcare SA develops and provides licenses for drugs. The firm offers services to oncology, cancer supportive care, pain and inflammation, gastrointestinal fields. The company was founded by Gabriele Braglia in 1976 and is headquartered in Pazzallo, Switzerland. | Corporate Officer/Principal | 01.01.1993 |
| Biofarma Lda. | Corporate Officer/Principal | 01.01.1985 |
| RECIPHARM AB (PUBL) | Direktor/Vorstandsmitglied | - |
Ausbildung von Carlos von Bonhorst
| University of Lisbon | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Helsinn Healthcare SA
Helsinn Healthcare SA Pharmaceuticals: MajorHealth Technology Helsinn Healthcare SA develops and provides licenses for drugs. The firm offers services to oncology, cancer supportive care, pain and inflammation, gastrointestinal fields. The company was founded by Gabriele Braglia in 1976 and is headquartered in Pazzallo, Switzerland. | Health Technology |
Recipharm AB
 Recipharm AB BiotechnologyHealth Technology Recipharm AB engages in the manufacture of pharmaceuticals and contract development services for pharmaceutical companies. It operates through the following segments: Manufacturing Sterile and Inhalation (MFG-SI); Manufacturing Solids and Others (MFG-SO); Development and Technology (D&T); and Others and Eliminations. The MFG-SI segment includes manufacturing of products on behalf of pharmaceutical companies and covers sterile and inhalation technologies as well as liquid vials and ampoules, lyophilisates, blow-fill-seal products, and inhalation. The MFG-SO segment produces products on behalf of pharmaceutical companies and covers tablets, capsules, semi-solids, and non-sterile liquids. The D&T segment focuses on pharmaceutical development services. The company was founded by Lars Rickard Backsell and Thomas Bengt Eldered in 1995 and is headquartered in Stockholm, Sweden. | Health Technology |
| Biofarma Lda. |